|
#1
30.09.2012, 15:51
|
|||
|
|||
|
Лечение гнойного бронхита
Уважаемые коллеги, прошу совета.
4 дня назад в подъезде произошло возгорание электропроводки. Получилось так, что мне пришлось "надышаться" этой гарью (прибл. 5-6 мин.). На следующий день появился сухой кашель. В течение последних двух дней при кашле отходит скудная вязкая гнойная мокрота серо-зеленого цвета. Кашель малопродуктивный, изнуряющий. Температурной реакции нет, слабость, небольшая потливость. Посоветуйте какое лучше применить лечение (без определения возбудителя и чувствительности)? Заранее благодарен за ответ! 
|
|
#2
30.09.2012, 17:37
|
|||
|
|||
|
Попробуйте принимать сумамед 250мг по схеме: в первый день 2 табл 1 раз, затем по 1 таблетке один раз в день.
Практический опыт показывает, что 5 дней недостаточно, лучше 7 дней. Амброгексал (амбробене) по 1 три раза в день. Кларитин (лоратодин) по 1 таблетке 1 раз в день. Теопек 0,1 по одной 2 раза после еды (при отсутствии обострения язвенной болезни, пароксизмальной мерцательной аритмии). Основное условие - отсутствие аллергии на перечисленные препараты.
|
|
#4
30.09.2012, 21:03
|
||||
|
||||
|
я бы посоветовал для начала сделать снимок грудной клетки.
|
|
#6
16.10.2012, 11:14
|
|||
|
|||
|
Азитромицин и внезапная смерть.
А вот и азитромицин оказался под подозрением в плане риска внезапной коронарной смерти: [Ссылки доступны только зарегистрированным пользователям ] Цитата: During 5 days of therapy, patients taking azithromycin, as compared with those who took no antibiotics, had an increased risk of cardiovascular death (hazard ratio, 2.88; 95% confidence interval [CI], 1.79 to 4.63; P<0.001) and death from any cause (hazard ratio, 1.85; 95% CI, 1.25 to 2.75; P=0.002). Patients who took amoxicillin had no increase in the risk of death during this period. Relative to amoxicillin, azithromycin was associated with an increased risk of cardiovascular death (hazard ratio, 2.49; 95% CI, 1.38 to 4.50; P=0.002) and death from any cause (hazard ratio, 2.02; 95% CI, 1.24 to 3.30; P=0.005), with an estimated 47 additional cardiovascular deaths per 1 million courses; patients in the highest decile of risk for cardiovascular disease had an estimated 245 additional cardiovascular deaths per 1 million courses. The risk of cardiovascular death was significantly greater with azithromycin than with ciprofloxacin but did not differ significantly from that with levofloxacin. http://forums.rusmedserv.com/showthread.php?t=235872
|
|
#7
16.10.2012, 11:18
|
|||
|
|||
|
Zithromax (azithromycin): FDA Statement on risk of cardiovascular death
Audience: Primary Care, Pharmacy ISSUE: FDA notified healthcare professionals that it is aware of the study published in the New England Journal of Medicine May 17, 2012 reporting a small increase in cardiovascular deaths, and in the risk of death from any cause, in persons treated with a 5-day course of azithromycin (Zithromax) compared to persons treated with amoxicillin, ciprofloxacin, or no drug. FDA is reviewing the results from this study and will communicate any new information on azithromycin and this study or the potential risk of QT interval prolongation after the agency has completed its review. BACKGROUND: Azithromycin belongs to a class of antibacterial drugs called macrolides, which have been associated with cardiovascular effects; specifically, prolongation of the QT interval. In 2011, FDA reviewed macrolide drug labeling information related to QT interval prolongation and TdP. The WARNINGS AND PRECAUTIONS section of the Zmax drug label (azithromycin extended release for oral suspension) was revised in March 2012 to include new information regarding risk for QT interval prolongation, which appears to be low. The drug labels for clarithromycin and erythromycin also contain information about QT interval prolongation in the WARNINGS section. FDA is in the process of updating risk information in the drug labels for additional macrolide antibacterial drugs. RECOMMENDATION: Patients taking azithromycin should not stop taking their medicine without talking to their healthcare professional. Healthcare professionals should be aware of the potential for QT interval prolongation and heart arrhythmias when prescribing or administering macrolides. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program: Complete and submit the report Online: [Ссылки доступны только зарегистрированным пользователям ] Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 [Ссылки доступны только зарегистрированным пользователям ]
|
Линейный вид
